WHO ICTRP trial
A multicenter, prospective, open, single-arm, Phase II clinical study exploring…
ChiCTR2300077760 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2300077760 |
|---|---|
| Public title | A multicenter, prospective, open, single-arm, Phase II clinical study exploring gemcitabine in combination with oxaliplatin and eribulin (GOE) in relapsed refractory advanced male germ cell tumors |
| Scientific title | A multicenter, prospective, open, single-arm, Phase II clinical study exploring gemcitabine in combination with oxaliplatin and eribulin (GOE) in relapsed refractory advanced male germ cell tumors |
| Primary sponsor | Sun Yat-sen University Cancer Center |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | CHINA |
| Conditions | Relapsed and refractory advanced male germ cell tumor |
| Interventions | treatment group:Gemcitabine:800 mg/m2, ivgtt, d1, d8,every 3 weeks; Oxaliplatin:130mg/m2, ivgtt, d8,every 3 weeks; Eribulin:1.4mg/m2, ivgtt, d1, d8,every 3 weeks; PEG-GCSF:6mg,H,d9,every 3 weeks; Up to 6 courses or until disease progression… |
| Registration date | Nov 18, 2023 |
| Target size | treatment group:43 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: